The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial
Abstract
Purpose: To evaluate the efficacy and safety of atrasentan (ABT-627), an endothelin-A receptor antagonist, in the treatment of asymptomatic, hormone-refractory prostatic adenocarcinoma. Patients and Methods: A double-blind, randomized, placebo-controlled clinical trial of hormone-refractory prostate cancer (HRPCa) patients was conducted in the United States and Europe. Two hundred eighty-eight asymptomatic patients with HRPCa and evidence of metastatic disease were randomly assigned to one of three study groups receiving a once-daily oral dose of placebo, 2.5 mg atrasentan, or 10 mg atrasentan, respectively. Primary end point was time to progression; secondary end points included time to prostate-specific antigen (PSA) progression, bone scan changes, and changes in bone and tumor markers. Results: The three treatment groups were similar in all baseline characteristics. Median time to progression in intent-to-treat (ITT) patients (n = 288) was longer in the 10-mg atrasentan group compared with the placebo group: 183 v 137 days, respectively; (P = .13). Median time to progression in evaluable patients (n = 244) was significantly prolonged, from 129 days (placebo group) to 196 days (10-mg atrasentan group; P = .021). For both ITT and evaluable populations in the 10-mg atrasentan group, median time to PSA progression was twice that of the placebo group (155 v 71 days; P = .002). Patients who received placebo continued to have significant increases from baseline in serum (lactate dehydrogenase [LDH]), a marker of disease burden; elevations in LDH were uniformly attenuated by atrasentan in the ITT population. Headache, peripheral edema, and rhinitis were primary side effects, typically of mild to moderate severity. Quality of life was not adversely affected by atrasentan. Conclusion: Atrasentan is an oral, targeted therapy with favorable tolerability and the potential to delay progression of HRPCa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
SF-36 health survey: Manual and interpretation guide
Ware, J. (2003) · Medical Entomology and Zoology · Cited by 11,424
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580
HUGGINS, C. (1941) · Archives of Surgery · doi:10.1001/archsurg.1941.01210140043004 · Cited by 1,499
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Self-citationKantoff, P. W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V., Trump, D., Winer, E. P., & Vogelzang, N. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2506 · Cited by 890
Self-citationLevin, E. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508103330607 · Cited by 711
Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997) · Urology · doi:10.1016/s0090-4295(97)00459-7 · Cited by 696
Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate
Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., & Simons, J. W. (1995) · Nature Medicine · doi:10.1038/nm0995-944 · Cited by 622
Self-citationEndothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer.
Nelson, J. B., Chan‐Tack, K. M., Hedican, S. P., Magnuson, S. R., Opgenorth, T. J., Bova, G. S., & Simons, J. W. (1996) · PubMed · Cited by 333
Self-citationSavarese, D. M., Halabi, S., Hars, V., Akerley, W. L., Taplin, M.-E., Godley, P. A., Hussain, A., Small, E. J., & Vogelzang, N. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2509 · Cited by 323
Self-citationPhase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer
Petrylak, D. P., MacArthur, R. B., O'Connor, J., Shelton, G., Judge, T. W., Balog, J., Pfaff, C., Bagiella, E., Heitjan, D. F., Fine, R., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.958 · Cited by 311
Hudes, G. R., Nathan, F., Khater, C., Haas, N., Cornfield, M., Giantonio, B., Greenberg, R., Gomella, L., Litwin, S., Ross, E., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.9.3156 · Cited by 272
Opgenorth, T. J., Adler, A. L., Calzadilla, S. V., Chiou, W. J., Dayton, B. D., Dixon, D. B., Gehrke, L. J., Hernandez, L., Magnuson, S. R., Marsh, K. C., et al. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12297-0 · Cited by 211
Bagnato, A., Salani, D., Castro, V. D., et al. (1999) · PubMed · Cited by 207
The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae
Takuwa, Y., Masaki, Τ., & Yamashita, K. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)90491-5 · Cited by 129
Clinical Trials in Relapsed Prostate Cancer: Defining the Target
Scher, H. I., Mazumdar, M., & Kelly, W. K. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.22.1623 · Cited by 120
Newling, D. W. W., Denis, L., & Vermeylen, K. (1993) · Cancer · Cited by 81
Bloomfield, D. J., Krahn, M. D., Neogi, T., Panzarella, T., Smith, T. J., Warde, P. R., Willan, A. R., Ernst, S., Moore, M. J., Neville, A. J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2272 · Cited by 75
Pagotto, U., Arzberger, T., Hopfner, Ú., Sauer, J., Renner, U., NEWTON, C. J., Lange, M., Uhl, E., Weindl, A., & Stalla, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118249 · Cited by 73
Venuti, A., Salani, D., Manni, V., Poggiali, F., & Bagnato, A. (2000) · The FASEB Journal · doi:10.1096/fj.00-0024com · Cited by 57
Cited by
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Self-citationTumor metastasis: mechanistic insights and clinical challenges
Steeg, P. S. (2006) · Nature Medicine · doi:10.1038/nm1469 · Cited by 2,134
Osteoblasts in prostate cancer metastasis to bone
Logothetis, C. J., & Lin, S.-H. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1528 · Cited by 614
The endothelin axis: emerging role in cancer
Nelson, J., Bagnato, A., Battistini, B., & Nisen, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc990 · Cited by 564
Self-citationBasic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases
Guise, T. A., Mohammad, K. S., Clines, G., Stebbins, E. G., Wong, D. H., Higgins, L. S., Vessella, R., Corey, E., Padalecki, S., Suva, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1007 · Cited by 539
Metadata
- Authors
- Carducci, M. A., Padley, R. J., Breul, J., Vogelzang, N. J., Zonnenberg, B. A., Daliani, D. D., Schulman, C. C., Nabulsi, A. A., Humerickhouse, R. A., Weinberg, M. A., Schmitt, J. L., & Nelson, J. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-02-15
- Volume
- 21
- Issue
- 4
- Pages
- 679-689
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2164828052
- Cited by
- 371
- References
- 23
- FWCI
- 34.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.